相关实验视频
Updated: Jul 10, 2025

Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
关于SABA用于喘临床决策的专家共识:德尔菲方法
Njira Lugogo1, Maeve O'Connor2, Maureen George3
1Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. nlugogo@med.umich.edu.
美国专家建议将短效β2-激动剂 (SABA) 的处方限制在每年不到三,以减少喘恶化和死亡风险. 在每次访问时定期监测SABA使用对于有效的喘管理至关重要.
科学领域:
- 肺部医学 肺部医学
- 临床实践指南 临床实践指南
- 喘管理 喘管理
背景情况:
- 短效β2-激动剂 (SABA) 是喘治疗的基石药物.
- 目前对SABA处方和监测的临床实践在美国临床医生之间存在很大差异.
- 缺乏明确的共识指导方针可能会导致SABA使用和相关风险低于最佳水平.
研究的目的:
- 建立美国专家领导的关于短效β2-激动剂 (SABA) 使用临床行动的共识.
- 引导医疗保健提供者管理SABA处方和患者监测.
- 为未来关于SABA使用门的喘指南制定提供信息.
主要方法:
- 一个经过修改的Delphi流程,涉及在线调查,论坛讨论和声明裁决.
- 第一阶段:对100名临床医生进行在线调查,以评估当前的SABA处方和监测实践.
- 第三阶段:由8名专家进行裁决,以达成对SABA使用关键建议的共识.
主要成果:
- 很大一部分临床医生 (21%) 没有咨询喘指南,12%的临床医生每年常规处方≥4个SABA.
- 专家们达成共识,每年≥3个SABA与恶化和喘相关死亡风险增加有关.
- 同意还支持在每次访问时征求SABA使用历史记录,并使用随时间推移的使用模式来指导SABA过度使用的干预措施.
结论:
- 专家一致认为,每年≥3个SABA作为表明风险增加的门.
- 对所有喘患者来说,建议在患者访问时定期征求SABA使用史.
- 未来的喘指南应该包含专家定义的SABA使用门,以促使临床行动.
更多相关视频
06:15Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
相关概念视频
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management
First, in...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction